Absci Shares Fall on Wider 4Q Loss, Lower Revenue

Dow Jones

03/25

By Connor Hart

Shares of Absci fell after the company widened its loss and logged lower revenue in the fourth quarter.

The stock declined 12%, to $2.64, in premarket trading Wednesday. Through Tuesday's close, shares are up 3.8% over the past year.

The biopharmaceutical company late Tuesday posted a widened loss of $29.6 million for its three months ended Dec. 31, compared with a loss of $29 million a year earlier. The quarterly loss came in at 20 cents a share, compared with analyst expectations for a loss of 18 cents a share, according to FactSet.

Revenue slipped 2.3% to $650,000, missing the $1.4 million that Wall Street modeled.

Founder and CEO Sean McClain said Absci made progress advancing its in-development therapies over the past year, noting that the company is implementing artificial intelligence to design therapeutics faster and cheaper than the broader industry.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

March 25, 2026 06:36 ET (10:36 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2622242022"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622242022\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622242022?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 18:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622242022","market":"nz","top_or_hot":-1,"title":"Absci Shares Fall on Wider 4Q Loss, Lower Revenue","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Absci fell after the company widened its loss and logged lower revenue in the fourth quarter. \n</p>\n<p>\n  The stock declined 12%, to $2.64, in premarket trading Wednesday. Through Tuesday's close, shares are up 3.8% over the past year. \n</p>\n<p>\n  The biopharmaceutical company late Tuesday posted a widened loss of $29.6 million for its three months ended Dec. 31, compared with a loss of $29 million a year earlier. The quarterly loss came in at 20 cents a share, compared with analyst expectations for a loss of 18 cents a share, according to FactSet. \n</p>\n<p>\n  Revenue slipped 2.3% to $650,000, missing the $1.4 million that Wall Street modeled. \n</p>\n<p>\n  Founder and CEO Sean McClain said Absci made progress advancing its in-development therapies over the past year, noting that the company is implementing artificial intelligence to design therapeutics faster and cheaper than the broader industry. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2026 06:36 ET (10:36 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Absci Shares Fall on Wider 4Q Loss, Lower Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbsci Shares Fall on Wider 4Q Loss, Lower Revenue\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-03-25 18:36</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Absci fell after the company widened its loss and logged lower revenue in the fourth quarter. \n</p>\n<p>\n  The stock declined 12%, to $2.64, in premarket trading Wednesday. Through Tuesday's close, shares are up 3.8% over the past year. \n</p>\n<p>\n  The biopharmaceutical company late Tuesday posted a widened loss of $29.6 million for its three months ended Dec. 31, compared with a loss of $29 million a year earlier. The quarterly loss came in at 20 cents a share, compared with analyst expectations for a loss of 18 cents a share, according to FactSet. \n</p>\n<p>\n  Revenue slipped 2.3% to $650,000, missing the $1.4 million that Wall Street modeled. \n</p>\n<p>\n  Founder and CEO Sean McClain said Absci made progress advancing its in-development therapies over the past year, noting that the company is implementing artificial intelligence to design therapeutics faster and cheaper than the broader industry. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2026 06:36 ET (10:36 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科學工具和服務","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2622242022","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622242022","pubTimestamp":1774434960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Absci fell after the company widened its loss and logged lower revenue in the fourth quarter.The stock declined 12%, to $2.64, in premarket trading Wednesday. Through Tuesday's close, shares are up 3.8% over the past year.The biopharmaceutical company late Tuesday posted a widened loss of $29.6 million for its three months ended Dec. 31, compared with a loss of $29 million a year earlier. The quarterly loss came in at 20 cents a share, compared with analyst expectations for a loss of 18 cents a share, according to FactSet.Revenue slipped 2.3% to $650,000, missing the $1.4 million that Wall Street modeled.Founder and CEO Sean McClain said Absci made progress advancing its in-development therapies over the past year, noting that the company is implementing artificial intelligence to design therapeutics faster and cheaper than the broader industry.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","ABSI":"Absci Corporation.","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"Absci股价因第四季度亏损扩大、收入下降而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABSI":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Absci fell after the company widened its loss and logged lower revenue in the fourth quarter. \n\n\n  The stock declined 12%, to $2.64, in premarket trading Wednesday. Through Tuesday's close, shares are up 3.8% over the past year. \n\n\n  The biopharmaceutical company late Tuesday posted a widened loss of $29.6 million for its three months ended Dec. 31, compared with a loss of $29 million a year earlier. The quarterly loss came in at 20 cents a share, compared with analyst expectations for a loss of 18 cents a share, according to FactSet. \n\n\n  Revenue slipped 2.3% to $650,000, missing the $1.4 million that Wall Street modeled. \n\n\n  Founder and CEO Sean McClain said Absci made progress advancing its in-development therapies over the past year, noting that the company is implementing artificial intelligence to design therapeutics faster and cheaper than the broader industry. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2026 06:36 ET (10:36 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}